Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: A report from the Children's Oncology Group

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 256-262

  Malempati, Suman ^a   Weigel, Brenda ^c   Ingle, Ashish M ^d   Ahern, Charlotte H ^e   Carroll, Julie M ^b   Roberts, Charles T ^a,b   Reid, Joel M ^f   Schmechel, Stephen ^c   Voss, Stephan D ^g   Cho, Steven Y ^h   Chen, Helen X ⁱ   Krailo, Mark D ^d   Adamson, Peter C ^j   Blaney, Susan M ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIXUTUMUMAB; SOMATOMEDIN C;

ADOLESCENT; ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FEVER; FIBROSARCOMA; FLUSHING; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOSARCOMA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; MALE; NEOPLASMS; SARCOMA, EWING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862907964     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.4355     Document Type: Article

References (38)

1. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928, 2008
2. Ayalon D, Glaser T, Werner H: Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 11:289-297, 2001 (Pubitemid 34257726)
3. El-Badry OM, Minniti C, Kohn EC, et al: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1:325-331, 1990
4. MacEwen EG, Pastor J, Kutzke J, et al: IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77-91, 2004
5. El-Badry OM, Romanus JA, Helman LJ, et al: Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 84:829-839, 1989 (Pubitemid 19228354)
6. Toretsky JA, Kalebic T, Blakesley V, et al: The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272:30822-30827, 1997 (Pubitemid 27527522)
7. Werner H, Re GG, Drummond IA, et al: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A 90:5828-5832, 1993 (Pubitemid 23176256)
8. LeRoith D, Werner H, Beitner-Johnson D, et al: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163, 1995
9. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195:127-137, 2003 (Pubitemid 36588961)
10. Scotlandi K, Manara MC, Nicoletti G, et al: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868-3876, 2005 (Pubitemid 40616368)
11. Tanno B, Mancini C, Vitali R, et al: Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 12:6772-6780, 2006 (Pubitemid 44876847)
12. Gansler T, Furlanetto R, Gramling TS, et al: Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 135:961-966, 1989 (Pubitemid 20026516)
13. Geoerger B, Daudigeous E, Debussche LR, et al: The anti insulin-like growth factor I receptor (IGF1-R) antibody AVE1642 exhibits anti-tumor activity against neuroblastoma cell lines and xenografts. Proc Am Assoc Cancer Res 47, 2006 (abstr 1222)
14. Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083, 2003 (Pubitemid 37022647)
15. Benini S, Manara MC, Baldini N, et al: Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7:1790-1797, 2001 (Pubitemid 32708650)
16. Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921, 2003 (Pubitemid 38064071)
17. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al: Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66:2391-2402, 2006
18. Rowinsky EK, Youssoufian H, Tonra JR, et al: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13:5549s-5555s, 2007 (Pubitemid 47510386)
19. Wu JD, Haugk K, Coleman I, et al: Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 12:6153-6160, 2006 (Pubitemid 44703781)
20. Wu KD, Zhou L, Burtrum D, et al: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56:343-357, 2007 (Pubitemid 46035904)
21. Allen GW, Saba C, Armstrong EA, et al: Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67:1155-1162, 2007
22. Wang Z, Chakravarty G, Kim S, et al: Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-4765, 2006 (Pubitemid 44297830)
23. Kolb EA, Morton C, Houghton PJ, et al: Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-IR antibody IMC-A12. Presented at 20th European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21-24, 2008
24. Higano CS, Yu EY, Whiting SH, et al: A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monocolonal antibody, in patients with advanced solid tumors. J Clin Oncol 25, 2007 (suppl; abstr 3505)
25. Rothenberg ML, Poplin E, Sandler AB, et al: Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. Presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007
26. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
28. Weber MM, Fottner C, Liu SB, et al: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086-2095, 2002 (Pubitemid 35253369)
29. Freier S, Eran M, Reinus C, et al: Relative expression and localization of the insulin-like growth factor system components in the fetal, child and adult intestine. J Pediatr Gastroenterol Nutr 40:202-209, 2005 (Pubitemid 40269743)
30. Giani C, Campani D, Rasmussen A, et al: Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer: Relationship with the most important morphological and biochemical prognostic parameters. Int J Biol Markers 17:90-95, 2002 (Pubitemid 34873793)
31. Rodon J, DeSantos V, Ferry RJ Jr, et al: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 7:2575-2588, 2008
32. Tolcher AW, Rothenberg ML, Rodon J, et al: A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 25, 2007 (suppl; abstr 3002)
33. Chou AJ, Merola PR, Sowers R, et al: IGF-I/IGF-I receptor signal transduction in osteosarcoma cell lines. Proc Am Assoc Cancer Res 45, 2004 (abstr 5193)
34. Shang Y, Mao Y, Batson J, et al: Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 7:2599-2608, 2008
35. Makawita S, Ho M, Durbin AD, et al: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 12:127-135, 2009
36. Leong S, Gore L, Benjamin R, et al: A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007
37. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11:129-135, 2010
38. Pappo AS, Patel S, Crowley J, et al: Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. J Clin Oncol 28:698s, 2010 (suppl 15; abstr 10000)